High‐dose ceftriaxone: Pharmacokinetic and pharmacodynamic insights in hospitalized patients with suspected sepsis in Thailand

Read full text
Authors: Nattapat Sangkakul, Apinya Boonpeng, Pisud Siripaitoon, Narongdet Kositpantawong, Siripen Kanchanasuwan, Sorawit Chittrakarn, Monchana Jullangkoon, Boonsri Charoenmak, Sarunyou Chusri
Cited by: 0
References: 20

Abstract

Aim Appropriate drug exposure is as crucial as proper selection and timely antibiotic administration in sepsis treatment. However, evidence is lacking regarding the current dosing regimen to achieve pharmacodynamic targets. This study aimed to describe ceftriaxone pharmacokinetic (PK) parameters and establish optimal dosing regimens for sepsis patients. Methods This study investigated the pharmacokinetics of ceftriaxone in sepsis patients receiving ceftriaxone 2 g every 12 or 24 h. Blood samples (11–14 samples per patient) were collected within the first 24 h post‐administration. PK parameters were estimated from unbound plasma concentrations using a nonlinear mixed‐effects modelling approach (NONMEM® software). Monte Carlo simulations were conducted to evaluate the probability of target attainment of standard and high‐dose ceftriaxone at various minimum inhibitory concentrations (MICs). Results Population PK analysis of 238 concentration–time data points from 20 patients revealed that a two‐compartment model best described ceftriaxone PK. Glomerular filtration rate (GFR), serum albumin, and body weight significantly affected clearance, volume of distribution, and intercompartmental clearance, respectively. Simulation demonstrated that standard dose of 2 g every 24 h was adequate for pathogens with MIC ≤1 mg L −1 . At higher MIC values, target attainment decreased, particularly in with GFR > 130 mL·min −1 , with twice‐daily dosing yielding higher exposures. Conclusion Standard ceftriaxone (2 g intravenous q 24 h, 30‐min infusion) provided adequate target attainment at low MICs in this exploratory study of suspected sepsis. PTA decreased with higher MICs and higher renal function, with higher dose regimens showing numerically greater exposures. These findings may help guide future studies on dosing optimization.

Fields of Study & Subjects

Antibiotics Pharmacokinetics and Efficacy Sepsis Diagnosis and Treatment Neutropenia and Cancer Infections

Publication details

Journal / source
British Journal of Clinical Pharmacology
Volume
92
Issue
7
Pages
2095–2108
Publication date
9 February 2026
Language
EN